Clinical trials
catalyst calendar across sponsors →Studies where ADMA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational · 4 with posted results
Held by 17 tracked-famous managers (D. E. Shaw & Co., Inc., Duquesne Family Office LLC, TWO SIGMA INVESTMENTS, LP, Fundsmith LLP, AQR CAPITAL MANAGEMENT LLC, +12 more) · FINRA short interest 8.8 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: 0 congress / 2 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)NCT05070455CmaxOpen-label · Treatment | Phase 4 | Unknown status | Biological: Asceniv™ | Primary Immune Deficiency | 12 | 2023-03-31 | 2022-09-16 |
| A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin ProductsNCT03037359observationalRate of Hypotension | — | Unknown status | Biological: Bivigam, Other | Primary Immune Deficiency Disorder | 200 | 2022-12-31actual | 2023-02-01 |
| Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16NCT03164967Temporally Associated Adverse EventsOpen-label · Other | Phase 4 | Completed | Biological: Bivigam | Humoral Immune Response | 16 | 2022-08-30actual | 2023-02-01 |
| Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)NCT01814800results2016-10-05Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))Open-label · Treatment | Phase 3 | Completed | Biological: RI-002 | Primary Immune Deficiency Disorder | 59 | Dec 2014actual | 2016-10-05 |
| RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV IllnessNCT00632463results2013-04-24Circulating RI-001 TiterRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: RI-001, RI-001, RI-001 | Upper Respiratory Tract Infection, Lower Respiratory Tract Infection | 21 | May 2010actual | 2013-04-24 |
| Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)NCT00538915results2012-03-26Rate of Serious Bacterial Infections (SBIs) Per Person-year on TreatmentOpen-label · Treatment | Phase 3 | Completed | Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | Primary Immune Deficiency Disorders (PIDD) | 63 | Jul 2009actual | 2021-07-30 |
| Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver TransplantationNCT00473824results2012-02-07Post Transplant Reduction in Viral Load (as Measured Quantitatively by Hepatitis C Virus (HCV) Reverse Transcription-Polymerase Chain Reaction (HCV RT-PCR)).Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: New sponsor's decision to pursue a redesigned clinical study | Biological: Hepatitis C Immune Globulin Intravenous (Human) 5% | Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation | 7 | Feb 2009actual | 2021-07-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19